Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt